GSK inks new rare disease drug development pact; ISTA wins FDA approval;

 @FierceBiotech: Myriad Genetics' shares rise on takeover talk. Report | Follow @FierceBiotech

> GlaxoSmithKline is priming the pump on a new rare disease drug development pact with Italy's Fondazione Telethon with a $14 million upfront. GSK, which has singled out rare diseases as one of its most important development initiatives, gets an exclusive license on a new gene therapy for "bubble babies" as well as additional gene therapies. The Italian research group also stands to gain milestones in the deal. Story

> The FDA has approved ISTA Pharmaceuticals' Bromday eye drops as a treatment for inflammation and pain following cataract surgery. Story

> Prosensa landed a £7.5 million milestone payment from GlaxoSmithKline on hitting a data milestone in its Phase IIa open label extension trial of GSK2402968. Prosensa release

> S*BIO announced that the European Commission has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis. S*BIO release

> Transposagen Biopharmaceuticals inked an exclusive licensing deal with Charles River Laboratories International for lab rats. Report

And Finally... Remember the old adage about the things that don't kill us make us stronger? There may be more truth to that than we know. A new multi-year study of the effects of adverse life events on mental health has found that adverse experiences do, in fact, appear to foster subsequent adaptability and resilience, with resulting advantages for mental health and well being. Release

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.